• The 16th edition of BioAsia, an annual falgship international and technology convention to be held on 25-27 February 2019, in HICC Hyderabad.
Bio Asia 2019 : Life Sciences 4.0 – Disrupt the disruption : 50 + Countries ; 70+ High profile speakers ; 800+ Corporates; 1000+ Partnering Meetings.
Hyderabad, India, February 22, 2019 : BioAsia 2019, the international life sciences convention, will be held from February 25th-27th at HICC, Hyderabad. The 16th edition of the prestigious event is organized by the Industries and Commerce Department in partnership with Government of India, Department of Biotechnology, Ministry of Science and Technology, Federation of Asian Biotech Associations (FABA) and Pharmaceutical Export Promotion Council (Pharmexcil).
Technology Conferences of BioAsia is a Science-Business bridge, that aims to bring together a trans-disciplinary environment for driving innovation in the life sciences industry. The tech conferences have been carefully structured in order to leverage technology trends for business relationships and help you put technology in the development relay across the world through co-development opportunities. While presenting an opportunity to explore partnerships and channels for extending businesses between industry and academia, BioAsia’s tech conferences will cover contemporary developments in research and will assist in building capabilities to break the technology development resistors for smooth flow of technology and collaborations.
This year – THEME – Disrupt The Disruption
Healthcare is being reimagined globally as a result of scientific and technological advances. Ubiquity of mobile, peer-to-peer sharing tools, and experience of engaging personalized services in other areas of their lives (for e.g. retail and transportation industries) is changing consumers into super consumers. Pricing pressures are forcing Governments / healthcare authorities to prioritize better health outcomes at reduced costs. While true innovation will continue to be relevant, the government is increasingly promoting the prescription of generics and biosimilar.
Digital health start-ups and technology entrants are already moving aggressively into the mainstream by developing innovative and low cost products, services and solutions.
It is critical for all companies to invest strategically and differentially in the capabilities that create future value for all stakeholders. Life sciences companies in India, must determine how they can seize the upside of disruption in today’s transformative age to:
- Maintain leadership in the evolving generics industry
- Start gaining share in the biosimilars and personalized medicines market
BioAsia 2019 is themed on Life Sciences 4.0 where the global industry experts will share their thoughts on global trends and ramifications for all industry stakeholders viz. companies, policy makers, healthtech companies, startups, hospitals, scientists, etc.
Disrupt the disruption :
As per Klaus Schwab, Founder and Executive Chairman of the World Economic Forum, fourth industrial revolution is evolving at an exponential rather than a linear pace. These technological advancements are resulting in changing stakeholder expectations (physicians, patients, etc.) and blurring boundaries between industries (resulting in a new set of competitors or potential partners in the market)
When there is disruption across all industries, being in denial is not an option. One key remedy to survive in this world of disruption is to change the game internally by accelerating the speed for innovation and execution. Future success will require a lot of experimentation, as well as some failures. Agility and innovation will become core strengths and critical differentiators for the leading pharma companies.
For more details about event visit here : http://2019.bioasia.in/index.html